Literature DB >> 25225168

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.

K A W Wadt1, L G Aoude2,3, P Johansson2, A Solinas4, A Pritchard2, O Crainic4, M T Andersen1, J F Kiilgaard5, S Heegaard5,6, L Sunde7, B Federspiel8, J Madore9, J F Thompson9,10, S W McCarthy4,9,10, A Goodwin11, H Tsao12, G Jönsson13, K Busam14, R Gupta4,10, J M Trent15, A-M Gerdes1, K M Brown16, R A Scolyer4,9,10, N K Hayward2.   

Abstract

We report four previously undescribed families with germline BRCA1-associated protein-1 gene (BAP1) mutations and expand the clinical phenotype of this tumor syndrome. The tumor spectrum in these families is predominantly uveal malignant melanoma (UMM), cutaneous malignant melanoma (CMM) and mesothelioma, as previously reported for germline BAP1 mutations. However, mutation carriers from three new families, and one previously reported family, developed basal cell carcinoma (BCC), thus suggesting inclusion of BCC in the phenotypic spectrum of the BAP1 tumor syndrome. This notion is supported by the finding of loss of BAP1 protein expression by immunochemistry in two BCCs from individuals with germline BAP1 mutations and no loss of BAP1 staining in 53 of sporadic BCCs consistent with somatic mutations and loss of heterozygosity of the gene in the BCCs occurring in mutation carriers. Lastly, we identify the first reported recurrent mutation in BAP1 (p.R60X), which occurred in three families from two different continents. In two of the families, the mutation was inherited from a common founder but it arose independently in the third family.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BAP1; BCC; cancer predisposition syndrome; germline mutation; melanoma; unknown primary tumor

Mesh:

Substances:

Year:  2014        PMID: 25225168     DOI: 10.1111/cge.12501

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  35 in total

Review 1.  Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Authors:  Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward
Journal:  J Natl Cancer Inst       Date:  2018-12-01       Impact factor: 13.506

Review 2.  BAP1, a tumor suppressor gene driving malignant mesothelioma.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  Mesothelioma: recent highlights.

Authors:  Michele Carbone; Haining Yang
Journal:  Ann Transl Med       Date:  2017-06

Review 4.  Update in genetic susceptibility in melanoma.

Authors:  Miriam Potrony; Celia Badenas; Paula Aguilera; Joan Anton Puig-Butille; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Ann Transl Med       Date:  2015-09

5.  Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.

Authors:  Raffit Hassan; Betsy Morrow; Anish Thomas; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Meghana Gadiraju; Vasiliki Panou; Shaojian Gao; Idrees Mian; Javed Khan; Mark Raffeld; Snehal Patel; Liqiang Xi; Jun S Wei; Mary Hesdorffer; Jingli Zhang; Kathleen Calzone; Arpita Desai; Emerson Padiernos; Christine Alewine; David S Schrump; Seth M Steinberg; Hedy L Kindler; Mary-Claire King; Jane E Churpek
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

Review 6.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

7.  Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.

Authors:  Yuwaraj Kadariya; Mitchell Cheung; Jinfei Xu; Jianming Pei; Eleonora Sementino; Craig W Menges; Kathy Q Cai; Frank J Rauscher; Andres J Klein-Szanto; Joseph R Testa
Journal:  Cancer Res       Date:  2016-02-19       Impact factor: 12.701

8.  Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.

Authors:  Mitchell Cheung; Yuwaraj Kadariya; Jacqueline Talarchek; Jianming Pei; Jill A Ohar; Omar R Kayaleh; Joseph R Testa
Journal:  Cancer Lett       Date:  2015-09-26       Impact factor: 8.679

Review 9.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

Review 10.  Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.

Authors:  Thomas Wiesner; Heinz Kutzner; Lorenzo Cerroni; Martin C Mihm; Klaus J Busam; Rajmohan Murali
Journal:  Pathology       Date:  2016-01-18       Impact factor: 5.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.